Busulfan
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Busulfan
- Pharmacist Assessment Report
- Busulfan: Alkylating agent for conditioning before transplant → myelodysplastic syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Busulfan: Alkylating agent for conditioning before transplant → myelodysplastic syndrome
One-Sentence Summary
Busulfan is a bifunctional alkylating agent that cross-links DNA and ablates bone marrow, and it is used mainly as a conditioning drug before stem cell transplant. The TxGNN model predicts it may be useful for myelodysplastic syndrome, with 39 listed clinical trials and 19 publications in the data compiled for this report. Its role would be as a conditioning component within an allogeneic transplant strategy, not as a stand-alone MDS therapy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | myelodysplastic syndrome |
| TxGNN Prediction Score | 0.9962 |
| Evidence Level | L1 |
| India Market Status | Listed in a compiled Indian medicine price dataset (7 of 7) – CDSCO approval status is not included in this data |
| Number of Listed Products | 7 (valid: 7) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Based on known information, busulfan is an alkylating agent that cross-links DNA and causes myeloablation.
Allogeneic hematopoietic stem cell transplantation is the only potentially curative approach for eligible patients with higher-risk MDS. Busulfan-based conditioning clears the malignant clone and makes room for donor stem cells to engraft. This is the mechanistic link between busulfan and MDS.
The supporting studies test busulfan as part of multi-drug regimens (with fludarabine, cyclophosphamide, cladribine, venetoclax or decitabine). The evidence therefore supports busulfan as a transplant conditioning backbone, not as a single agent for MDS.
Clinical Trial Evidence
The compiled data lists many trials that include MDS patients. The most relevant are shown below.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00005866 | Phase 3 | Completed | 240 | Busulfan-TBI vs cyclophosphamide-TBI conditioning in advanced MDS or MDS-related AML |
| NCT00822393 | Phase 3 | Completed | 570 | Treosulfan-based vs reduced-intensity busulfan-based conditioning in AML or MDS |
| NCT04708054 | Phase 2/3 | Recruiting | 324 | Venetoclax added to fractionated busulfan regimen in high-risk AML and MDS |
| NCT05453552 | Phase 2/3 | Unknown | 242 | G-CSF + decitabine + busulfan/cyclophosphamide vs G-CSF + decitabine + BF in high-risk MDS |
| NCT04713956 | Phase 2/3 | Unknown | 242 | Same comparison in RAEB-1, RAEB-2 and AML secondary to MDS |
| NCT00502905 | Phase 2 | Completed | 200 | IV busulfan + fludarabine conditioning for allogeneic transplant in AML and MDS |
| NCT02250937 | Phase 2 | Active, not recruiting | 116 | Venetoclax with timed-sequential busulfan, cladribine and fludarabine in AML and MDS |
| NCT01643668 | Phase 2 | Completed | 34 | Reduced-intensity busulfan/clofarabine conditioning; small, single-arm |
| NCT01168219 | Phase 2 | Completed | 68 | Busulfan, fludarabine and ATG plus azacitidine in high-risk MDS and older AML |
| NCT06247917 | Phase 2 | Unknown | 59 | Flu-Bu-Mel conditioning in MDS |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31606445 | 2020 | RCT | Lancet Haematol | Treosulfan vs reduced-intensity busulfan plus fludarabine in older AML or MDS patients (non-inferiority phase 3) |
| 36702138 | 2023 | RCT | Lancet Haematol | G-CSF + decitabine + busulfan-cyclophosphamide vs busulfan-cyclophosphamide on relapse in MDS or secondary AML |
| 42285355 | 2026 | RCT | Transplant Cell Ther | Two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS |
| 35617104 | 2022 | Cohort | Am J Hematol | Final analysis: treosulfan vs reduced-intensity busulfan in older AML and MDS patients |
| 40079242 | 2025 | Review | Am J Hematol | Allogeneic transplant is the only potentially curative therapy for MDS and myelofibrosis |
| 34692485 | 2021 | Meta-analysis | Front Oncol | Reduced-intensity vs myeloablative conditioning in AML and MDS |
| 33425740 | 2020 | Systematic review | Front Oncol | Long-term outcomes of treosulfan- vs busulfan-based conditioning in MDS and AML |
| 34489555 | 2021 | Registry analysis | Bone Marrow Transplant | Fludarabine/busulfan vs busulfan/cyclophosphamide for MDS |
| 35296446 | 2022 | Registry analysis | Transplant Cell Ther | Myeloablative vs reduced-intensity fludarabine/busulfan in MDS |
| 38197938 | 2024 | Cohort | Blood Adv | Venetoclax/azacitidine maintenance after Ven + fludarabine/busulfan conditioning in high-risk MDS and AML |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 79518 | Emsulfan 60mg Injection | vial of 1 Injection | Not recorded |
| 30967 | Busulmax 2mg Tablet | strip of 25 tablets | Not recorded |
| 31343 | Busuphan 2mg Tablet | strip of 10 tablets | Not recorded |
| 30520 | Busulmax 60 Injection | vial of 10 ml Injection | Not recorded |
| 27875 | Bufatas IV Injection | vial of 10 ml Injection | Not recorded |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent) |
| Myelosuppression Risk | High (myeloablative at conditioning doses) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC with differential, liver and renal function; therapeutic drug monitoring of busulfan exposure is used in trials with targeted dosing |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Drug Interactions: 228 interactions were recorded. Examples include metronidazole (Major), aprepitant (Moderate) and miconazole (Moderate), and levofloxacin (Minor). Many others, such as dexamethasone, ondansetron, omeprazole and morphine, have an unclassified severity level.
- Conditions flagged in the compiled data as concerns for busulfan include neutropenia, thrombocytopenia, agranulocytosis, anemia, pulmonary fibrosis, epilepsy, and infectious diseases. These are not taken from label text and need confirmation against the package insert.
- A literature review notes that secondary malignancy risk with busulfan exposure is considered low but poorly characterized (PMID 37856098).
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two completed Phase 3 randomized trials (NCT00005866, NCT00822393) and several randomized publications directly address busulfan-based conditioning in MDS. The evidence supports busulfan only as part of transplant conditioning regimens in selected patients, not as a stand-alone MDS treatment.
To proceed, the following is needed:
- Package insert warnings and contraindications for the Indian-marketed products
- Mechanism of action data to complete the mechanistic analysis
- Clear restriction of use to transplant-conditioning settings in transplant-eligible patients
- A myelosuppression and toxicity monitoring plan, including dose targeting and supportive care
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.